

CLAIMS

What is claimed is:

1. ~~A method~~ Use of Prasinezumab in the manufacture of a medicament for maintaining or slowing decline in motor function in a subject having Parkinson's disease or at risk of Parkinson's disease ~~comprising administering to the subject a regimen of Prasinezumab~~, wherein the maintaining comprises reducing Parkinson's disease progression as demonstrated by delaying time to progression of at least a 5-point progression in MDS-UPDRS Part III, and the slowing decline comprises at least one of the following:
 - (a) slowing decline the patient's MDS-UPDRS Part III motor examination score,
 - (b) slowing decline in one or more of speech, facial expression, rigidity, finger tapping, hand movements, pronation-supination movements of hands, toe tapping, leg agility, arising from chair, gait, freezing of gait, postural stability, posture, tremor of hands, rest tremor amplitude, constancy of rest tremor, or Hoehn and Yahr Stage;
 - (c) improving bradykinesia;and wherein the ~~regimen of Prasinezumab medicament~~ comprises 1000-5000 mg of Prasinezumab and is to be administered at intervals of 3 to 5 weeks.
2. The ~~method-use~~ of claim 1, wherein the slowing decline of the patient's motor examination score comprises an improvement of at least 4%, 17%, 18%, 24%, 25%, 33%, 35%, 39%, 45%, 52%, 63%, 64%, 68%, 71%, 74%, 76%, or 109% compared to a placebo after one year of treatment.
3. The ~~method-use~~ of claim 1, wherein the slowing decline of the patient's motor examination score comprises an improvement of at least 18%, 24%, 25%, 33%, 35%, or 45% compared to a placebo after one year of treatment.
4. The ~~method-use~~ of claim 1, wherein the subject has been diagnosed as a mild motor-predominant subtype, a diffuse-malignant subtype, or an intermediate subtype of Parkinson's.
5. The ~~method-use~~ of claim 1, wherein the subject has been diagnosed as a diffuse-malignant subtype of Parkinson's.

6. The ~~method-use~~ of any one of claims 1-5, further comprising ~~administering to the subject that~~ a monoamine oxidase (“MAO”) inhibitor is to be administered to the subject.
7. The ~~method-use~~ of claim 6, wherein the MAO inhibitor is a MAO-B inhibitor.
8. The ~~method-use~~ of any one of claims 1-7, wherein the Prasinezumab medicament is to be administered intravenously.
9. ~~A method~~ Use of Prasinezumab in the manufacture of a medicament for maintaining or increasing cerebral blood flow in a subject having Parkinson’s disease or at risk of Parkinson’s disease, ~~comprising administering to the subject a regimen of Prasinezumab comprising wherein the medicament comprises~~ 1000-5000 mg of Prasinezumab and is to be administered at intervals of 3 to 5 weeks.
10. The ~~method-use~~ of claim 9, wherein cerebral blood flow is maintained or increased in the putamen.
11. The ~~method-use~~ of claim 9, wherein cerebral blood flow is maintained or increased in the pallidum.
12. The ~~method-use~~ of claim 9, wherein cerebral blood flow is maintained or increased in the premotor cortex.
13. The ~~method-use~~ of any one of claims 9-12, wherein blood flow is assessed by changes in magnetic resonance-arterial spin labeling (MRI-ASL).
14. The ~~method-use~~ of any one of claims 9-13, wherein the Prasinezumab medicament is to be administered intravenously.
15. ~~A method~~ Use of Prasinezumab in the manufacture of a medicament for improving cognitive function in a subject having Parkinson’s disease or at risk of Parkinson’s disease ~~comprising administering to the subject a regimen of Prasinezumab comprising wherein the medicament comprises~~ 1000-5000 mg of Prasinezumab and is to be administered at intervals of 3 to 5 weeks.

16. The ~~method-use~~ of claim 15, wherein the subject does not have an impairment in cognitive function.
17. The ~~method-use~~ of claim 15, wherein the improvement of cognitive function is measured by Montreal Cognitive Assessment (MoCA), and wherein the improvement is at least 0.2 on a MoCa scoring scale.
18. The ~~method-use~~ of any one of claims 15-17, wherein the ~~Prasinezumab medicament~~ is to be administered intravenously.
19. The ~~method-use~~ of any one of claims 15-18, further comprising ~~administering to the subject that~~ a MAO-B inhibitor is to be administered to the subject.
20. The ~~method-use~~ of any one of claims 15-19, wherein the subject is treatment naïve, was diagnosed as having PD in the last two years, or was previously treated with a MAO-B inhibitor.
21. The ~~method-use~~ of any one of claims 1-20, wherein the subject has a weight greater than 65 kg and ~~is administered wherein the medicament comprises~~ a dose of 4500 mg Prasinezumab and is to be administered once every 4 weeks.
22. The ~~method-use~~ of any one of claim 1-20, wherein the subject has a weight less than 65 kg and ~~is administered wherein the medicament comprises~~ a dose of 3500 mg Prasinezumab and is to be administered once every 4 weeks.
23. The ~~method-use~~ of any one of claims 1-20, wherein the ~~subject is administered medicament comprises~~ a dose of 1500 mg antibody and is to be administered to the subject every 4 weeks.
24. The ~~method-use~~ of any one of claims 1-24, wherein the medicament is to be administered to the subject ~~receives Prasinezumab~~ once every 4 weeks for at least 52 weeks.
25. The ~~method-use~~ of any one of claims 1-24, wherein the subject is male.

26. ~~A method of treating a subject having~~ Use of Prasinezumab in the manufacture of a medicament for treating Parkinson's disease or a subject at risk of Parkinson's disease ~~comprising administering to the subject a regimen of Prasinezumab~~, wherein the treating comprises

- (a) reducing Parkinson's disease progression as demonstrated by delaying time to progression of at least a 5-point progression in MDS-UPDRS Part III, or
- (b) slowing decline in motor function comprising at least one of the following
 - i. slowing decline the patient's MDS-UPDRS Part III motor examination score;
 - ii. slowing decline in one or more of speech, facial expression, rigidity, finger tapping, hand movements, pronation-supination movements of hands, toe tapping, leg agility, arising from chair, gait, freezing of gait, postural stability, posture, tremor of hands, rest tremor amplitude, constancy of rest tremor, or Hoehn and Yahr Stage;
 - iii. improving bradykinesia,

and

wherein the ~~regimen of Prasinezumab medicament~~ comprises 1000-5000 mg of Prasinezumab and is to be administered at intervals of 3 to 5 weeks.

27. The ~~method-use~~ of claim 26, wherein the subject has been diagnosed as a mild motor-predominant subtype, a diffuse-malignant subtype or an intermediate subtype of Parkinson's.

28. The ~~method-use~~ of claim 27, wherein the subject has been diagnosed as a diffuse-malignant subtype of Parkinson's.

29. The ~~method-use~~ of any one of claims 26-28, wherein the slowing decline of the patient's motor examination score comprises an improvement of at least 4%, 17%, 18%, 24%, 25%, 33%, 35%, 39%, 45%, 52%, 63%, 64%, 68%, 71%, 74%, 76%, or 109% compared to a placebo after one year of treatment.

30. The ~~method-use~~ of any one of claims 26-29, wherein the ~~Prasinezumab medicament~~ is to be administered intravenously.

31. The ~~method-use~~ of any one of claims 26-30, further comprising ~~administering to the subject that~~ a monoamine oxidase (“MAO”) inhibitor is to be administered to the subject.

32. The ~~method-use~~ of claim 31, wherein the MAO inhibitor is a MAO-B inhibitor.

33. The ~~method-use~~ of any one of claims 26-32, wherein the subject is treatment naïve, was diagnosed as having PD in the last two years, or was previously treated with a MAO-B inhibitor.

34. The ~~method-use~~ of any one of claims 26-33, wherein the subject has a weight greater than 65 kg and ~~is administered a dose of wherein the medicament comprises~~ 4500 mg Prasinezumab and is to be administered once every 4 weeks.

35. The ~~method-use~~ of any one of claims 26-33, wherein the subject has a weight less than 65 kg and ~~is administered a dose of wherein the medicament comprises~~ 3500 mg Prasinezumab and is to be administered once every 4 weeks.

36. The ~~method-use~~ of any one of claims 26-33, wherein ~~the subject is administered a dose of the medicament comprises~~ 1500 mg antibody and is to be administered every 4 weeks.

37. The ~~method-use~~ of any one of claims 26-36, wherein ~~the subject receives Prasinezumab the medicament is to be administered to the subject~~ once every 4 weeks for at least 52 weeks.

38. The ~~method-use~~ of any one of claims 26-37, wherein the subject is male.